Carbonic anhydrases (CAs, EC 4.2.1.1) are ubiquitous metalloenzymes in mammals, being involved in numerous biosynthetic processes, including gluconeogenesis, lipogenesis and ureagenesis. It has recently emerged that CA inhibitors (CAIs) targeting the mitochondrial isoforms CA VA and VB have potential as novel antiobesity drugs. This Editorial discusses the biochemical and biological rationale for the use of CAIs in the management of obesity.

Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity / C. T. Supuran. - In: EXPERT OPINION ON EMERGING DRUGS. - ISSN 1472-8214. - STAMPA. - 17:(2012), pp. 11-15. [10.1517/14728214.2012.664132]

Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity.

SUPURAN, CLAUDIU TRANDAFIR
2012

Abstract

Carbonic anhydrases (CAs, EC 4.2.1.1) are ubiquitous metalloenzymes in mammals, being involved in numerous biosynthetic processes, including gluconeogenesis, lipogenesis and ureagenesis. It has recently emerged that CA inhibitors (CAIs) targeting the mitochondrial isoforms CA VA and VB have potential as novel antiobesity drugs. This Editorial discusses the biochemical and biological rationale for the use of CAIs in the management of obesity.
2012
17
11
15
C. T. Supuran
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/776370
Citazioni
  • ???jsp.display-item.citation.pmc??? 16
  • Scopus 76
  • ???jsp.display-item.citation.isi??? 72
social impact